Inhibrx (INBX) Stock Price, News & Analysis

Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $13.97 to $14.77
• 50-Day Range: $10.84 to $15.37
• 52-Week Range: $10.80 to $17.79
• Volume: 52,259 shs
• Average Volume: 106,350 shs
• Market Capitalization: $210.92 million
• P/E Ratio: 0.12
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Inhibrx Stock Analysis - MarketRank™

Inhibrx scored higher than 58% of companies evaluated by MarketBeat, and ranked 426th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Inhibrx.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inhibrx are expected to decrease in the coming year, from $104.88 to ($12.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibrx is 0.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibrx is 0.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.30.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.16% of the float of Inhibrx has been sold short.

Short Interest Ratio / Days to Cover

Inhibrx has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Inhibrx has recently decreased by 6.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibrx does not currently pay a dividend.

Dividend Growth

Inhibrx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.21

Percentage of Shares Shorted

7.16% of the float of Inhibrx has been sold short.

Short Interest Ratio / Days to Cover

Inhibrx has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Inhibrx has recently decreased by 6.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Inhibrx has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Inhibrx this week, compared to 1 article on an average week.

Search Interest

1 people have searched for INBX on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibrx insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.09% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INBX Stock Analysis - Frequently Asked Questions

How have INBX shares performed this year?

Inhibrx's stock was trading at $15.40 on January 1st, 2025. Since then, INBX shares have decreased by 5.6% and is now trading at $14.53.
View the best growth stocks for 2025 here.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.55) by $0.25.

When did Inhibrx IPO?

Inhibrx (INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx's major shareholders?

Inhibrx's top institutional investors include HighTower Advisors LLC (6.02%), Woodline Partners LP (2.48%), Slotnik Capital LLC (1.98%) and Acadian Asset Management LLC (1.33%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Global Investors Lp Viking, Jon Faiz Kayyem and Kristiina Md Vuori.
View institutional ownership trends.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Video Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/13/2025
• Next Earnings (Estimated): 6/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INBX
• CIK: 1739614
• Web: www.inhibrx.com
• Phone: 858-795-4220
• Fax: N/A
• Employees: 166
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $116.75
• Trailing P/E Ratio: 0.13
• Forward P/E Ratio: 0.14
• P/E Growth: N/A
• Net Income: -$154.96 million
• Net Margins: N/A
• Pretax Margin: 110,409.73%
• Return on Equity: -113.74%
• Return on Assets: -80.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.70
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: $200 thousand
• Price / Sales: 1,062.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,476,000
• Free Float: 11,262,000
• Market Cap: $212.58 million
• Optionable: Optionable
• Beta: N/A